Ariana Pharma

Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company has expanded its operations to the United States since 2012. Ariana Pharma's flagship technology, KEM® Artificial Intelligence (xAI), is instrumental in revolutionizing drug development processes. This technology enables the introduction of personalized medicine clinical trial design, optimization of clinical endpoints, identification of biomarkers of therapeutic response, and potential synergistic therapies.

With a recent $2.30M Series A investment at 09 July 2008 from Vizille Capital Innovation, Ariana Pharma has garnered further support for its innovative endeavors. The company's focus on combining clinical data with omic data, immunological readouts, microbiota, Patient Reported Outcomes (PRO), and Real World Evidence (RWE) data showcases its commitment to comprehensive and innovative approaches in drug development.

With a growing number of successful therapeutic development programs, Ariana Pharma has leveraged KEM® to develop Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. The company's expertise in advanced data analytics, drug development, and regulatory processes positions it as a pivotal player in translating findings into innovative clinical development plans and obtaining regulatory approvals. Ariana Pharma continues to be a frontrunner in leveraging AI for precision medicine and clinical trial optimization within the pharmaceutical industry.